Most patients with moderately to severely active Crohn’s disease who achieved endoscopic response and remission after 52 ...

The government-funded study was small and experts say it's not yet clear how safe these drugs are for people who don't need ...

When patients can’t access their MHT patches, they may consider switching to different formulations, such as tablets or gels.

The FDA has approved the sBLA for once every 4 weeks lecanemab-irmb (Leqembi®) intravenous maintenance dosing.

Eli Lilly presents positive results from VIVID-2 open-label extension study of Omvoh to treat Crohn's disease at Crohn's and Colitis Congress: Indianapolis Monday, February 10, 20 ...

CNW/ - Pharmascience Canada is proud to announce the launch of  Pr  pms-RUPATADINE (rupatadine), a treatment that helps relieve nasal and non-nasal ...

INDIANAPOLIS - Eli Lilly and Company (NYSE: NYSE:LLY), a pharmaceutical giant with a market capitalization of $783.7 billion ...

PEDMARQSI is the First and Only Approved Therapy in the EU and U.K. for the Prevention of Ototoxicity, or Hearing Loss, Induced by Cisplatin Chemotherapy in Patients 1 month to <18 Years of Age with ...

Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2024 earnings call. [Operator instructions] I would now like to turn the conference over to your host, Mike Czapar, ...

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...